Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Aptamer Group Plc ( (GB:APTA) ).
Aptamer Group plc has announced a new development contract with a rare disease biopharmaceutical company, potentially worth up to £155,000, to develop Optimer binders for therapeutic monitoring. The agreement supports Aptamer’s strategy of leveraging fee-for-service revenue paired with licensing opportunities, aiming to enhance shareholder value and align with its growth objectives.
More about Aptamer Group Plc
Aptamer Group plc operates in the life sciences industry, specializing in the development of novel Optimer® binders. These binders are used to enable innovation within the sector, with a focus on therapeutic and clinical applications.
YTD Price Performance: -67.83%
Average Trading Volume: 18,000,063
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.36M
Find detailed analytics on APTA stock on TipRanks’ Stock Analysis page.
